Poland· PL-100383860
Alecensa
A alectinib product containing alectinibum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Alectinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED03 (alectinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Alectinib · ATC L01ED03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alectinib costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alectinib · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$204.18
The record
At a glance
URPL (Poland)- Active substance
- Alectinibum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01ED03
- ATC class
- Alectinib
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05902768001143
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
96 interactions on record for alectinib.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alectinib · interactions on record
96 records
- 10 severe
- 86 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- Aminolevulinic acidL01XD04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alectinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainALECENSA 150 MG CAPSULAS DURASRoche Registration Gmbh
- United StatesALECENSAGenentech, Inc.
- United KingdomAlecensa 150mg capsulesOriginalis B.V.
- CzechiaALECENSARoche Registration GmbH, Grenzach-Wyhlen
- SwitzerlandAlecensa
- FinlandAlecensaRoche Registration GmbH
- FranceALECENSA 150 mg, géluleROCHE REGISTRATION (ALLEMAGNE)
- BelgiumAlecensa 150 mgRoche Registration
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Alecensa
- Liechtenstein · Alecensa
- Norway · Alecensa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d1b8a971-a452-45ec-afbd-9aa0a1a62dcd GET /v1/drugs/d1b8a971-a452-45ec-afbd-9aa0a1a62dcd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "150 mg",
"packaging": "05902768001143 ¦ Rpz ¦ EU/1/16/1169/001 ¦ 120047\n224 kaps.\nRpz ¦ EU/1/16/1169/002 ¦ 126348\n240 kaps.",
"substance": "Alectinibum 150 mg",
"common_name": "Alectinibum",
"pl_product_id": "100383860",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about alectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.